Regeneron Pharmaceuticals, Inc. Dossier
Qualitative Analysis
Business overview
Regeneron Pharmaceuticals, Inc. is a leading fully integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious medical conditions. Founded in 1988 and headquartered in Tarrytown, New York, the company leverages its proprietary VelociSuite antibody technologies and the Regeneron Genetics Center as core innovation engines to discover therapeutic candidates internally. Regeneron's commercial base is anchored by blockbuster franchises, including Eylea and Eylea HD in retinal diseases, and its global collaboration with Sanofi for Dupixent in immunology. The company also markets Libtayo in oncology, Kevzara in rheumatoid arthritis, and other specialty biologics.
Research as of 5 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Regeneron is advancing approximately 50 clinical product candidates across eye, allergic and inflammatory, oncology, cardiovascular and metabolic, neurological, hematologic, infectious and rare diseases, including registrational programs such as cemdisiran and Otarmeni.
Expected impact: The initiative is intended to diversify growth beyond established franchises through additional indications, new modalities and new commercial medicines.
Regeneron is constructing a drug-substance manufacturing facility in Saratoga Springs, New York, participating in the FDA PreCheck Pilot Program, and expanding outsourced U.S. manufacturing through its FUJIFILM Diosynth Biotechnologies agreement.
Expected impact: The investments should increase domestic biologics capacity, support a larger commercial and clinical portfolio, and improve supply-chain resilience.
Regeneron licensed ex-China rights to olatorepatide, a dual GLP-1/GIP receptor agonist, to complement its internal obesity programs; Hansoh subsequently reported positive Phase 3 results in Chinese adults with obesity or overweight.
Expected impact: Olatorepatide gives Regeneron a late-stage incretin asset that can be evaluated alone or within a broader strategy focused on sustained weight loss and preservation of healthy body composition.
Regeneron and Parabilis Medicines are combining Regeneron's antibody capabilities with Parabilis' cell-penetrant Helicon peptide platform to discover stand-alone Helicon therapies and Antibody-Helicon Conjugates against historically difficult or undruggable intracellular targets.
Expected impact: The platform could extend Regeneron's antibody franchise into intracellular biology and create differentiated therapeutics across multiple disease areas.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
The acquisition expanded Regeneron's genetic-medicine and hearing-loss capabilities by adding three gene-therapy programs for congenital monogenic hearing loss, including the program now known as Otarmeni.
Financial impact: The transaction had an approximately $109 million equity value based on consideration payable at closing and could reach approximately $213 million if contingent-value-right milestones are achieved.
Strategic Partnerships
Combines Regeneron's antibody discovery and targeting capabilities with a cell-penetrant peptide platform designed to modulate difficult intracellular proteins.
Terms: $50 million upfront payment, $75 million equity commitment, up to approximately $2.2 billion in additional potential milestones, and tiered royalties.
Adds a Phase 3 dual GLP-1/GIP receptor agonist to Regeneron's obesity portfolio and creates combination-development optionality with internal metabolic programs.
Terms: $80 million upfront payment, up to $1.93 billion in development, regulatory and sales milestones, and low-double-digit royalties on applicable sales outside the licensed-out territories.
Expands domestic manufacturing capacity for Regeneron's biologic medicines and complements its internal New York manufacturing investments.
Terms: Regeneron describes the manufacturing-capacity agreement as valued at more than $3 billion.
The collaboration underpins Dupixent and Kevzara commercialization; Dupixent global net sales reached $5.998 billion in the second quarter of 2026.
Terms: Sanofi records global Dupixent and Kevzara sales, while Regeneron recognizes its share of collaboration profits. The Sanofi Development Balance was fully repaid by June 30, 2026 and ceases reducing collaboration revenue beginning in the third quarter.